Akpụkpọ ahụ nke mkpụrụ ndụ
Molekula Tumor Boodi (MTB) bụ otu ndị ọkachamara ahụike raara onwe ha nye iji nyochaa ọrịa kansa siri ike ịgwọ ma nye oghere nlekọta ahụike onwe onye.[1] A na-akpọkwa ya sekwensin Tumor Board ma a na-akọwa ya site n' itinye n'ọrụ miri emi nke nyocha nke mkpụrụ ndụ (dịka genomics na transcriptomics) maka otu onye ọrịa. [2] A na-ewere Molekula Tumor Boodi dị ka ihe bara uru maka ụdị ọrịa kansa nke ọgwụgwọ na-adịghị arụ ọrụ, dịka ọmụmaatụ, n'ihe gbasara sarcomas dị iche iche.[1] ndị na-ahụ maka ọrịandị na-ahụ maka ọrịa ndị ọzọ mejupụtara bọọdụ ndị ahụ, nke dịgasị iche site n'ụlọ ọrụ gaa n'ụlọ ọrụ, mana ọ nwere ike ịgụnye ndị na-ahụ Maka mkpụrụ ndụ ihe nketa, ndị na-amụ banyere ozi ndụ na ndị na-emepụta ihe ndị dị ndụ.[1] A na-ewere MTBs dị ka imeziwanye Nsonaazụ ahụike maka ndị ọrịa nwere akpụ nwere profaịlụ Molekula pụrụ iche.[3]
Ọtụtụ ụlọ ọrụ ejirila Molekula Tumo Boodi mee ihe, dị ka ebe ọgwụ Dartmouth-Hitchcock, ụlọ ọgwụ Johns Hopkins [4] na ebe kansa Moffitt [5]
- ↑ (September 2020) "Molecular Tumor Boards in Clinical Practice". Trends in Cancer 6 (9): 738–744. DOI:10.1016/j.trecan.2020.05.008. PMID 32517959.
- ↑ (November 2011) "Personalized oncology through integrative high-throughput sequencing: a pilot study". Science Translational Medicine 3 (111): 111ra121. DOI:10.1126/scitranslmed.3003161. PMID 22133722.
- ↑ (October 2020) "Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy". Nature Communications 11 (1): 4965. DOI:10.1038/s41467-020-18613-3. PMID 33009371.
- ↑ (November 2017) "Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board". JCO Precision Oncology 2017 (1): 1–19. DOI:10.1200/po.16.00046. PMID 30003184.
- ↑ (February 2017) "Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience". The Oncologist 22 (2): 144–151. DOI:10.1634/theoncologist.2016-0195. PMID 28179575.